Oral insulin (antigen-specific immunotherapy)

Oral insulin is one of the oldest ideas in T1D prevention with one of the most stubborn track records: give insulin by mouth not to lower glucose, but as an antigen — a way to teach the immune system to tolerate the very protein it attacks first. It is the cleanest test of "antigen-specific immunotherapy": calm the attack without the broad immune suppression that other approaches carry.

Screening: who is even eligible

You can only offer a prevention therapy to people you've found. T1D is now understood as a staged disease: stage 1 is two or more islet autoantibodies with normal glucose, stage 2 adds dysglycemia, and stage 3 is the clinical diabetes everyone recognizes.¹ That staging matters because the risk is steep and predictable: children who develop multiple islet autoantibodies have roughly a 70% chance of clinical diabetes within 10 years , versus about 15% for a single antibody.² Two tiers of screening feed the trials: autoantibody screening in older children (the basis of programs like Fr1da, which showed population-level capillary-blood screening of young children is feasible),³ and genetic screening of newborns to find the ~1% of infants whose gene profile gives a >10% risk of autoimmunity — the entry point for infant prevention.⁴

Therapy: mechanism, trials, and the honest result

Mechanism: swallowed insulin is broken down before it can affect blood sugar, so it acts purely as an antigen presented to gut-associated immune tissue, aiming to expand regulatory ("calming") T cells. A dose-finding study (Pre-POInT) showed this is real and dose-dependent: 67.5 mg/day produced a tolerogenic immune response in 5 of 6 children, with no hypoglycemia and no new autoantibodies — establishing both a dose and a clean safety profile.⁵

But the prevention trials have been neutral. The original DPT-1 oral insulin trial (relatives, stage 1–2) found no overall delay, with only a hypothesis-generating signal in people with high insulin-autoantibody titers.⁶ TrialNet then ran a confirmatory trial (NCT00419562): again no effect in the main group (hazard ratio 0.87), but a striking delay in the high-risk "secondary stratum 1" (HR 0.45).⁷ Most recently, GPPAD's POInT primary-prevention trial (NCT03364868) gave high-dose oral insulin to 1,050 genetically at-risk infants starting at 4–7 months — the boldest test yet. The headline was again neutral: 10% of the insulin group vs 9% of placebo developed multiple autoantibodies or diabetes (HR 1.12).⁸ The twist that keeps the field alive: a gene–treatment interaction — children with insulin-gene (INS) risk variants were protected from progression, while those with non-risk variants fared slightly worse — hinting that the average result buried opposite effects in different people.⁹

Safety and stages: across every trial, in healthy children and infants, oral insulin has been generally well tolerated, with no excess hypoglycemia and similar overall adverse-event rates. Rare low glucose readings occurred in both POInT arms.⁷⁸ That safety is exactly why it remains attractive for the youngest, healthiest candidates. Access: it is not approved anywhere for prevention and exists only inside research studies; contrast teplizumab, the one approved stage-2 therapy.¹

What's coming

POInT children are being followed to see whether the genotype-defined protection becomes a real delay in diabetes, and the consortium is explicitly pivoting toward personalized prevention — matching oral insulin (and dose) to the children whose genetics predict benefit, rather than treating everyone the same.⁹ If that pharmacogenetic story holds, oral insulin could re-emerge as a precision tool. For now, the honest verdict is: a safe idea, repeatedly neutral overall, kept alive by credible subgroup signals.